CA2950610A1 — Cyclodextrin-based polyanionic and non-ionic dendrimers
Assigned to UTI LP · Expires 2015-12-03 · 10y expired
What this patent protects
The present application provides polyanionic and non-ionic cyclodextrin-based compounds, and methods of manufacturing them. The compounds comprise a negatively-charged or neutral moiety (and, for polyanionic compounds, a suitable counter cation), one or more linkers, optionally o…
USPTO Abstract
The present application provides polyanionic and non-ionic cyclodextrin-based compounds, and methods of manufacturing them. The compounds comprise a negatively-charged or neutral moiety (and, for polyanionic compounds, a suitable counter cation), one or more linkers, optionally one or more bridging groups, a cyclodextrin, and one or more substituents on the cyclodextrin. The compounds can be used in pharmaceutical compositions, and as excipients or carriers of guest molecules.
Drugs covered by this patent
- Zulresso (BREXANOLONE) · Sage Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.